HAMP and anemia (phenotype): Based on our expanding knowledge of the pathways underlying inflammatory anaemia and specifically the role of hepcidin, new therapeutic strategies are emerging that attempt to block hepcidin activity either by directly interfering with hepcidin synthesis by affecting different inflammation- or iron-driven signalling pathways that regulate hepcidin expression (such as SMAD, STAT3, BMP, BMPR, or TMPRSS6) or by neutralizing hepcidin in the circulation [57,157,158,159,160] (Figure 1).